Novartis' oral multiple sclerosis drug meets main goal in late stage studies

Novartis reported that its oral drug remibrutinib met the primary endpoints in two late-stage studies, outperforming a rival therapy by reducing relapse rates in a type of multiple sclerosis. The results indicate clinical superiority on a key disease-activity metric, supporting potential upside to development and future commercial outlook.